Filing Flows › ENvue Medical (FEED) › Q2 2026 › vs Q2 2025
ENvue Medical (FEED) Q2 2026 vs Q2 2025 (year over year)
ENvue Medical's revenue fell $255K (-52%) from $494K in Q2 2025 to $239K in Q2 2026. The biggest changes: Nano Vibronix −$390K (-88%); ENvue +$135K (+276%).
ENvue Medical, Q2 2026: revenue $239K (-52% year over year), net loss $4.9M, operating cash flow −$2.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| ENvue | $184K | $49K | $135K | +276% |
| Nano Vibronix | $55K | $445K | −$390K | -88% |
| Revenue | $239K | $494K | −$255K | -52% |
| Other income, net | $573K | $67K | $506K | +755% |
| Income tax benefit | $2K | −$62K | $64K | — |
| Net loss | $4.9M | $4.0M | $928K | +23% |
| Costs & expenses | $5.7M | $4.5M | $1.2M | +26% |
| Operating costs | $5.7M | $4.5M | $1.2M | +28% |
| Cost of revenue | $505K | $529K | −$24K | -5% |
| Research & development | $510K | $1.0M | −$506K | -50% |
| Sales & marketing | $1.2M | $673K | $525K | +78% |
| General & admin | $3.5M | $2.3M | $1.2M | +55% |
| Operating cash sources | $4.9M | $4.0M | $928K | +23% |
| Depreciation & amortization | $219K | $364K | −$145K | -40% |
| Working capital & other | $2.0M | $224K | $1.8M | +788% |
| Cash used in operations | $2.7M | $3.4M | −$692K | -20% |
| Net loss absorbed | $4.9M | $4.0M | $928K | +23% |
Questions
How much did ENvue Medical's revenue grow year over year in Q2 2026?
ENvue Medical's revenue fell $255K (-52%) from $494K in Q2 2025 to $239K in Q2 2026.
What drove ENvue Medical's revenue change in Q2 2026?
Nano Vibronix −$390K (-88%); ENvue +$135K (+276%).